Across the U.S., millions of families are anxiously awaiting a decision on a new drug to treat Alzheimer’s disease. Yet if the drug reaches the market, the U.S. health system may have a hard time getting it to the people who might benefit. Professor emerita Soo Borson, PhD, is quoted.